Trials that use: Risk ratio / relative risk
New to this method? Read the tutorial →
4,715 results
- Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CVT-ISR First in Human Trial for Coronary In-Stent Restenosis: Complete Statistical AnalysisIndependent statistical analysis of CVT-ISR First in Human Trial for Coronary In-Stent Restenosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05731700).
- CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry: Complete Statistical AnalysisIndependent statistical analysis of CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis: Complete Statistical AnalysisIndependent statistical analysis of Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00001213).
- Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery: Complete Statistical AnalysisIndependent statistical analysis of Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04302545).
- CYTOFLOCIndependent statistical analysis of Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03529669).
- D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism: Complete Statistical AnalysisIndependent statistical analysis of D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- D-LUCSIndependent statistical analysis of Combined Pharmacotherapy for Cannabis Dependency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01020019).
- Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites: Complete Statistical AnalysisIndependent statistical analysis of Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites: primary endpoint results, effect estimate with confidence interval,…
- DACABIndependent statistical analysis of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02201771).
- Dacarbazine and Carmustine in Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Dacarbazine and Carmustine in Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01692691).
- Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance: Complete Statistical AnalysisIndependent statistical analysis of Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung: Complete Statistical AnalysisIndependent statistical analysis of Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- DAHHS-2Independent statistical analysis of Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Dailies Total 1 Sphere Contact Lenses: Complete Statistical AnalysisIndependent statistical analysis of Dailies Total 1 Sphere Contact Lenses: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05239494).
- DAILIES TOTAL1® Lens Centration in a Japanese Population: Complete Statistical AnalysisIndependent statistical analysis of DAILIES TOTAL1® Lens Centration in a Japanese Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02252133).
- Daily Disposable Comparison Study: Complete Statistical AnalysisIndependent statistical analysis of Daily Disposable Comparison Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02094677).
- Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: Complete Statistical AnalysisIndependent statistical analysis of Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02048722).
- Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- dal-GenEIndependent statistical analysis of Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Daprodustat Bioequivalence and Food Effect Study: Complete Statistical AnalysisIndependent statistical analysis of Daprodustat Bioequivalence and Food Effect Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03493386).
- DAR-PIAIndependent statistical analysis of DAR-901 TB Booster Vaccine to Prevent TB in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02712424).
- Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DARE-CIndependent statistical analysis of DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01743521).
- Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504153).
- Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00423735).
- Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- DATASIndependent statistical analysis of DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00157820).
- DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis: Complete Statistical AnalysisIndependent statistical analysis of DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03825315).
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: Complete Statistical AnalysisIndependent statistical analysis of DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- DEARIndependent statistical analysis of Dose Escalation and Remission (DEAR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00652145).
- Decision Aid for Therapeutic Options In Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Decision Aid for Therapeutic Options In Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02326597).
- Decision Making Tool for Firearm Storage: Complete Statistical AnalysisIndependent statistical analysis of Decision Making Tool for Firearm Storage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06382194).
- Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness: Complete Statistical AnalysisIndependent statistical analysis of Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Decision-aid on Breast Cancer Screening: Complete Statistical AnalysisIndependent statistical analysis of Decision-aid on Breast Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03097653).
- Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00903760).
- Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00382200).
- Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: Complete Statistical AnalysisIndependent statistical analysis of Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- DEEPBLOCKIndependent statistical analysis of Deep Neuromuscular Block for Laparoscopic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03034577).
- DeFACTOIndependent statistical analysis of Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01233518).